CSL is an Australian biotech company with a market cap of more than A$130 billion dollars, making it the country’s third biggest listed company, behind BHP and Commonwealth Bank.
In this week’s podcast, Rebecca Jones asks Bloomberg News reporter Amy Bainbridge and senior editor Jason Gale how CSL became a market favorite and about the headwinds it’s facing in the post-pandemic era.

What the Iran War Means for Interest Rates, Inflation and Stocks
14:22

The Rising Cost of Retirement (And What Super Funds Are Doing About It)
17:43

Inside the Housing Backlash in Sydney’s Wealthiest Suburbs
11:59